http://www.gurufocus.com/news.php?id=739...

Biogen Idec Inc (BIIB) COO Robert A Hamm sells 2,854 Shares

Nov. 05, 2009- COO of Biogen Idec Inc (BIIB) Robert A Hamm sells 2,854 shares of BIIB on 11/04/2009 at an average price of $42.81 a share.

IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product Rituxan and our most advanced product candidate ZEVALIN are for use in the treatment of certain B-cellnon-Hodgkin's lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis rheumatoidarthritis and lupus). Biogen Idec Inc has a market cap of $12.36 billion; its shares were traded at around $42.8 with a P/E ratio of 11.4 and P/S ratio of 3.

BIIB is in the portfolios of Carl Icahn of Icahn Capital Management LP, PRIMECAP Management, Edward Owens of Vanguard Health Care Fund, David Dreman of Dreman Value Management.
***
Insiders' Positions with BIIB

Sell:: Director Robert W Pangia sold 15,000 shares of BIIB stock on 09/29/2009 at the average price of $52
(BIIB pps decreased by 17.7% since 9/29)

Sell:: Director Bruce Ross sold 1,700 shares of BIIB stock on 06/24/2009 at the average price of $48.53
(BIIB pps decreased by 11.8% since 6/24)

Sell:: Director Nancy Leaming sold 820 shares of BIIB stock on 06/24/2009 at the average price of $48.52
(BIIB pps decreased by 11.8% since 6/24)

Sell:: COO Robert A Hamm sold 3,194 shares of BIIB stock on 06/22/2009 at the average price of %50.07
(BIIB pps decreased by 14.5% since 6/22)